NPPA has revised ceiling prices of 31 formulations of Schedule-I under Drugs (Price Control) Amendment Order, 2016 and retail prices of 7 formulations under DPCO, 2013 in related notification/order dated 08.10.2016.

Name of the scheduled formulations are Ganciclovir Powder for Injection, Fluoxetine Tablet, Omeprazole Tablet, Propranolol Capsule, Nitrofurantoin Capsule, Azithromycin Capsule, Imatinib Capsule, Lithium Tablet, Diazepam Injection, Phenytoin Injection, Thiopentone Powder for Injection, Ketamine Injection, Propofol Injection, Bupivacaine Injection, Adrenaline Injection, Lignocaine Injection Doxycycline Tablet, Vincristine Injection and Metronidazole Oral Liquid.

Retail price of scheduled formulations are Clopidogrel + Rosuvastatin Capsule, Cholecalciferol Drops (Arbivit - 3 Forte), Ceftazidime + Tazobactam Injection (Zytaz-T), Glimepiride +Metformin HCl Tablet (Glucoryl M4 Forte), Tacrolimus Capsule (Tacromus0.25) and Propranolol +Flunarizine Capsule (Migrafin – P).

Retail price is applicable only to the individual manufacturers/marketeers i.e. who have applied for the same by submitting Form-I for price fixation/revision as stipulated under DPCO, 2013 and subject to fulfillment of all the applicable statutory requirements as laid down by the government under relevant statutes/rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturers/marketing companies.

The concerned manufacturers of these formulations shall furnish quarterly return to the NPPA, in respect of production/import and sale of product in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Manufacturers in case intending to discontinue above said formulations, shall furnish information to the NPPA, in respect of discontinuation of the production and/or import of above said formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.

In case the retail price of any of the formulations is not complied with, as per instant price notification and notes specified, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.

Consequent to the issue of retail price of the formulations as specified in this notification, the price order(s) if any, issued for concerned manufacturer/marketeer prior to said date of notification, stand(s) superseded.